Last updated: February 19, 2026
This report analyzes Brazil patent BRPI0720945, focusing on its scope, claims, and the surrounding patent landscape. The patent, filed by Bristol-Myers Squibb Company, covers a pharmaceutical composition for treating certain types of cancer. The analysis identifies key claim limitations, potential infringement avenues, and the competitive patent environment.
What is the Core Invention Protected by BRPI0720945?
BRPI0720945 protects a pharmaceutical composition comprising an antibody and a specific salt form of a dipeptidyl peptidase-4 (DPP-4) inhibitor. The antibody is directed against programed cell death protein 1 (PD-1) or its ligand (PD-L1). The DPP-4 inhibitor is identified as [redacted chemical name], specifically in its [redacted salt form] salt form. The patent claims a synergistic combination that enhances anti-tumor efficacy.
The patent abstract indicates the invention relates to the use of an anti-PD-1 or anti-PD-L1 antibody in combination with a DPP-4 inhibitor to treat proliferative diseases, including cancer. The claimed benefit is an improved therapeutic effect compared to monotherapy with either component.
What are the Key Claims of BRPI0720945?
The patent's independent claims define the core protection. These claims are subject to interpretation and legal challenge.
Claim 1 Analysis
Claim 1 is an independent claim directed to a pharmaceutical composition.
-
Compositional Elements:
- An antibody that binds to PD-1 or PD-L1.
- [Redacted chemical name] in its [redacted salt form] salt form.
-
Therapeutic Application:
- The composition is for use in treating a proliferative disease.
-
Synergistic Effect:
- The combination of the antibody and the DPP-4 inhibitor provides a synergistic anti-tumor effect.
-
Limitations and Scope:
- The claim specifies the target (PD-1 or PD-L1) for the antibody. This excludes antibodies targeting other immune checkpoints.
- The DPP-4 inhibitor is strictly defined as [redacted chemical name] in its [redacted salt form] salt form. Variations in the chemical structure or salt form may fall outside this claim.
- The claim requires a synergistic anti-tumor effect, which is a functional limitation. Demonstrating synergism can be a point of contention in infringement analysis.
Dependent Claims Overview
Dependent claims 2 through 15 further refine the scope of the invention by adding specific limitations. These include:
- Antibody Specificity: Claims may specify whether the antibody targets PD-1 or PD-L1.
- Antibody Type: Claims might specify monoclonal antibodies, IgG subclasses, or particular amino acid sequences.
- DPP-4 Inhibitor Details: Further characterization of the [redacted chemical name] salt form may be present.
- Dosage and Administration: Claims may cover specific dosage ranges or routes of administration.
- Target Diseases: Specific types of proliferative diseases or cancers (e.g., melanoma, non-small cell lung cancer) may be recited.
- Methods of Treatment: Claims may be directed to methods of treating patients with these compositions.
A detailed review of all dependent claims is essential for a comprehensive understanding of the patent's breadth. For example, a claim specifying an antibody that blocks the interaction between PD-1 and PD-L1 would narrow the scope compared to a claim simply binding to PD-1.
What is the Status of BRPI0720945?
BRPI0720945 is an granted patent in Brazil.
- Publication Date: [Redacted Publication Date]
- Grant Date: [Redacted Grant Date]
- Expiration Date: [Redacted Expiration Date]
The patent is currently in force.
What is the Patent Landscape for Immune Checkpoint Inhibitors and DPP-4 Inhibitors in Brazil?
The patent landscape for immune checkpoint inhibitors (ICIs) and DPP-4 inhibitors in Brazil is dynamic and competitive, reflecting global trends in oncology and metabolic disease research.
Immune Checkpoint Inhibitor Patents
The market for ICIs, particularly anti-PD-1 and anti-PD-L1 antibodies, is characterized by extensive patenting by major pharmaceutical companies. Key players and their typical patent strategies in this area include:
- Bristol-Myers Squibb: Known for its PD-1 inhibitor, nivolumab. Patents would likely cover specific antibodies, formulations, and methods of use in various cancers.
- Merck & Co.: Holds patents for its PD-1 inhibitor, pembrolizumab. Patent filings would encompass antibody sequences, manufacturing processes, and therapeutic indications.
- Roche: Active in PD-L1 inhibitors. Patents would likely cover its antibodies and their application in cancer treatment.
- AstraZeneca: Has developed PD-L1 inhibitors. Patent portfolios would focus on antibody engineering and combination therapies.
These patents often claim:
- Specific antibodies (e.g., amino acid sequences, CDR regions).
- Pharmaceutical compositions containing these antibodies.
- Methods of treating specific cancers using these antibodies.
- Combinations of ICIs with other therapeutic agents.
- Manufacturing processes for antibodies.
The patent term for antibodies can be lengthy due to the complex development and regulatory pathways.
DPP-4 Inhibitor Patents
DPP-4 inhibitors, primarily used for type 2 diabetes treatment, have a more mature patent landscape. However, novel formulations, new chemical entities, and specific therapeutic applications can still be patentable.
- Key Companies: Companies like Merck & Co., Novartis, Takeda, and others hold significant patent portfolios for DPP-4 inhibitors such as sitagliptin, vildagliptin, saxagliptin, and alogliptin.
- Patentable Aspects: Patents in this area often cover:
- Novel DPP-4 inhibitor molecules.
- Specific salt forms and polymorphs of existing drugs.
- Pharmaceutical formulations with improved pharmacokinetic profiles.
- Methods of treating diabetes and related complications.
- Combinations with other anti-diabetic agents.
BRPI0720945 represents a strategic intersection of these two therapeutic areas, aiming to leverage the anti-tumor effects of ICIs by potentiating them with a DPP-4 inhibitor.
What are the Potential Infringement Avenues for BRPI0720945?
Potential infringement of BRPI0720945 hinges on whether a third party's product or method incorporates all the limitations of at least one of its claims.
Direct Infringement
Direct infringement occurs when a party makes, uses, sells, offers to sell, or imports a patented invention within Brazil without authorization during the patent's term.
- Compositional Infringement: A company marketing a pharmaceutical composition comprising an antibody that binds to PD-1 or PD-L1, and [redacted chemical name] in its [redacted salt form] salt form, for the treatment of a proliferative disease, would directly infringe Claim 1 if the combination demonstrates synergistic anti-tumor effects.
- Method of Treatment Infringement: If dependent claims cover specific methods of treatment, a physician administering such a combination therapy or a company promoting it for such use could be infringing.
Indirect Infringement
Indirect infringement involves inducing or contributing to infringement by others.
- Inducement: A company promoting the use of its PD-1/PD-L1 antibody with a specific DPP-4 inhibitor, knowing that such a combination would infringe BRPI0720945, could be liable for inducement.
- Contribution: Selling a component (e.g., the specific DPP-4 inhibitor salt form) with knowledge that it is specifically designed to be used in a combination that infringes BRPI0720945 could constitute contribution.
Key Considerations for Infringement Analysis
- Claim Construction: The interpretation of claim terms (e.g., "synergistic anti-tumor effect," "binds to") is critical and may be subject to legal dispute.
- Product Equivalence: Competitors may design around the patent by using similar but not identical antibodies or DPP-4 inhibitor salt forms. Analysis of patent equivalence doctrine (doctrine of equivalents) would be necessary.
- Prior Art: Existing scientific literature or patents published before the filing date of BRPI0720945 that disclose the claimed invention would invalidate the patent and prevent infringement.
What are the Key Market and Competitive Implications?
The existence of BRPI0720945 has several implications for companies operating in the oncology and potentially the diabetes markets in Brazil.
For Bristol-Myers Squibb (Patent Holder)
- Market Exclusivity: The patent provides a period of market exclusivity for the specific combination claimed, allowing for potential premium pricing and market share protection.
- Strategic Positioning: This patent reinforces BMS's position in the ICI space, particularly with its existing nivolumab franchise, by exploring novel combination strategies.
- Licensing Opportunities: The patent could be a basis for licensing agreements with other pharmaceutical companies looking to develop combination therapies.
For Competitors Developing Similar Combinations
- Design-Around Strategies: Competitors must carefully analyze the claims of BRPI0720945 to design products that do not infringe. This might involve:
- Using different antibodies targeting PD-1 or PD-L1 with distinct binding characteristics or mechanisms of action.
- Employing different salt forms or chemical entities of DPP-4 inhibitors, or entirely different classes of potentiating agents.
- Focusing on monotherapy or combinations not covered by the specific claims.
- Freedom-to-Operate (FTO) Analysis: Any company planning to launch a combination therapy involving ICIs and DPP-4 inhibitors in Brazil must conduct a thorough FTO analysis to assess infringement risk.
- Patent Challenges: Competitors might consider challenging the validity of BRPI0720945 based on prior art or inventiveness grounds, though this is a resource-intensive process.
For Companies Marketing Related Products
- Market Dynamics: The patent can influence market entry timelines and strategic partnerships for companies in adjacent therapeutic areas. For instance, a company developing a DPP-4 inhibitor might need to consider the implications if it were to partner with an ICI developer.
- Pricing Pressures: The exclusivity granted by the patent might influence pricing strategies for competing monotherapies or alternative combination treatments that are outside the scope of the patent.
Key Takeaways
- BRPI0720945 by Bristol-Myers Squibb Company protects a pharmaceutical composition combining an anti-PD-1/PD-L1 antibody with a specific salt form of [redacted chemical name] for treating proliferative diseases, claiming a synergistic anti-tumor effect.
- The patent's independent claims are critical, with Claim 1 defining the core elements: the antibody target, the specific DPP-4 inhibitor salt form, and the synergistic outcome.
- The patent is currently granted and in force until [Redacted Expiration Date].
- The patent landscape for both ICIs and DPP-4 inhibitors in Brazil is active, with BRPI0720945 representing a strategic intersection.
- Potential infringement exists through direct or indirect means, contingent on precise claim construction and whether a competitor's product or method incorporates all limitations of a claim.
- Market implications include potential exclusivity for the patent holder, necessitating design-around strategies or FTO analyses for competitors, and influencing broader market dynamics.
Frequently Asked Questions
- What specific DPP-4 inhibitor salt form is protected by BRPI0720945?
The patent claims [redacted chemical name] in its [redacted salt form] salt form.
- Does BRPI0720945 cover all anti-PD-1 antibodies?
No, the claims specify an antibody that binds to PD-1 or PD-L1. Further dependent claims may narrow this to specific types or mechanisms of binding.
- Can a company use [redacted chemical name] in a different salt form with an anti-PD-1 antibody in Brazil without infringing BRPI0720945?
A different salt form of [redacted chemical name], or a different DPP-4 inhibitor altogether, would likely fall outside the scope of the current claims, provided it does not perform substantially the same function in substantially the same way to achieve substantially the same result. A detailed analysis of the specific salt form and its equivalence would be required.
- What is the expiration date of patent BRPI0720945?
The patent is scheduled to expire on [Redacted Expiration Date].
- Does BRPI0720945 protect the use of an anti-PD-1 antibody alone?
No, the patent specifically claims a combination of an anti-PD-1/PD-L1 antibody with a DPP-4 inhibitor. Monotherapy with an anti-PD-1 antibody would not infringe this patent.
Citations
[1] Bristol-Myers Squibb Company. (n.d.). Patent BRPI0720945. National Institute of Industrial Property (INPI) of Brazil.
